Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
Part of paid clinical trials in Philadelphia, Pennsylvania.
- Sponsor
- University of Pennsylvania
- Study ID
- NCT02945345
- Status
- Recruiting
Conditions
- Dermatomyositis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Study Details
The Evaluation of Clinical Responsiveness Using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), established in 2008, is a one-site database study conducted at the University of Pennsylvania. The database has yielded valuable information and clinical insights into the pathophysiology, disease processes, including psychological responses, treatments and quality of life associated with dermatomyositis. The CDASI database incorporates the Cutaneous Dermatomyositis Disease Area and Severity Index), a validated outcome measure of disease responsiveness in patients, and other assessment tools, surveys and patient information to help validate the clinical course and quality of life of patients with dermatomyositis. The CDASI database has led to publication of comparison studies of CDASI and other clinical instruments and the effect of dermatomyositis on Quality of Life (QoL). The CDASI database is an ongoing resource that enables clinicians to evaluate the evolving clinical changes, treatment modalities and patient response to a challenging disease. Data will be analysed over a 5 years.
Key Dates
- Start date
- Jun 30, 2008
- Status verified
- Mar 2026
- Primary completion
- Jan 2, 2030
- Completion
- Jan 2, 2030
Study Design
- Enrollment
- 300 participants (estimated)
Primary Outcome Measure
Cutaneous Dermatomyositis Disease Area and Severity Index [ Time Frame: through study completion, an average of 1 year ]
Central Contacts
- Victoria Werth, MD215-615-2940
- Joyce Okawa, RN215-615-2940
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Hospital of the University of Pennsylvania | Philadelphia | Pennsylvania | 19104 | Victoria P Werth, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Philadelphia, PA
Related Studies
- Environmental Risk Factors for the Anti-synthetase SyndromeRecruiting · National Institute of Environmental Health Sciences (NIEHS) · Miami, Florida
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory MyopathyPHASE3 · Enrolling By Invitation · argenx · Phoenix, Arizona
- RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory MyopathyPHASE2/PHASE3 · Recruiting · Cabaletta Bio · Orange, California